LifeMD (LFMD) to Release Quarterly Earnings on Wednesday

LifeMD (NASDAQ:LFMD) is anticipated to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect LifeMD to announce earnings of ($0.1457) per share and revenue of $49.1570 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The company had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. On average, analysts expect LifeMD to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Price Performance

Shares of LifeMD stock opened at $3.50 on Monday. The business has a fifty day simple moving average of $4.46 and a 200 day simple moving average of $3.98. The stock has a market cap of $169.26 million, a PE ratio of 70.01 and a beta of 2.02. LifeMD has a 12 month low of $2.56 and a 12 month high of $12.72.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of LifeMD in the fourth quarter worth about $36,000. Jain Global LLC bought a new position in shares of LifeMD during the 4th quarter valued at about $45,000. Quarry LP bought a new position in shares of LifeMD during the 3rd quarter valued at about $52,000. Tower Research Capital LLC TRC grew its position in shares of LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the period. Finally, Invesco Ltd. grew its position in shares of LifeMD by 18.8% in the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock valued at $83,000 after purchasing an additional 3,870 shares during the period. 35.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on LFMD. UBS Group restated a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research note on Tuesday, May 26th. Zacks Research downgraded shares of LifeMD from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Weiss Ratings raised shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.14.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.